Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina

Introduction

Over the past decade, vaccines have resurfaced as an attractive commercial proposition for Pharma. The developed world has been the initial focus of vaccine makers due to the better healthcare infrastructure and higher price levels. However, facing increasingly saturated markets in the West, companies are looking to expand into new geographies, such as Latin America's emerging markets.

Scope

*Strategic analysis of key domestic vaccine companies as well as the position of major international players

*Thorough assessment of the market environment for vaccines in Brazil, Mexico and Argentina

*Review of existing vaccine recommendations, coverage rates and promising future indications

*In-depth discussion of strengths, weaknesses, opportunities and threats for each market from a vaccine maker's perspective

Highlights

Striving to achieve self-sufficiency in vaccine supply, Brazil has created a strong, state-controlled vaccine industry. The requirement for technology transfer partnerships with domestic companies for international vaccine makers targeting the Brazilian public sector can facilitate market entry, but reduces the long-term market opportunity.

In the absence of a strong domestic vaccine industry, Mexico and Argentina heavily depend on vaccine imports. Partnerships with local developers and distributors can gain international players an advantage in market penetration and winning national tenders.

As a consequence of increasing wealth and growing awareness for vaccination, emerging private sector markets in all three countries offer a promising opportunity, particularly to manufacturers of novel, high-price vaccines which currently have small chances of being integrated into routine vaccination schedules.

Reasons to Purchase

*Review portfolios and deals for key domestic vaccine companies as well as the position of major international vaccine makers

*Gain insight into the market environment for vaccines through a review of demographic, economic and regulatory trends

*Understand challenges, unmet needs and future opportunities for vaccine makers targeting Brazil, Mexico and Argentina

[Studien Infos ausblenden]

Overview 1
Catalyst 1
Summary 1
About Datamonitor healthcare 2
About the Infectious Diseases pharmaceutical analysis team 2
Executive Summary 3
Scope of the analysis 3
Datamonitor insight into vaccines in emerging markets (Latin America) 3
Related reports 5
Upcoming reports 5
Table of Contents 6
1. Overview of the three main Latin American Emerging markets for vaccines 7
Key findings 7
Brazil and Mexico are promising potential markets for vaccine developers due to their large birth cohorts and growing population sizes 7
The increasing wealth in Latin America has led to the emergence of a promising private sector market for vaccines 8
There is a large unmet need for vaccines against endemic diseases in Latin America 10
Vaccination coverage and recommendations vary across the key emerging Latin American markets 11
There are significant differences between the vaccines markets of Brazil, Mexico and Argentina 13
2. Brazil 20
Key findings 20
General characteristics 21
Demographics 21
Economics 24
Healthcare expenditure and access 25
The Brazilian vaccines market 28
Historic development 28
Current market situation 30
Key stakeholders in Brazil's vaccination system 34
Existing recommendations, coverage, available vaccines 35
Vaccination recommendations 35
Vaccination coverage 39
Available vaccines 41
Regulatory process for vaccines 43
Key vaccine players in Brazil 44
General overview 44
Multinational corporations 46
GlaxoSmithKline 47
Sanofi Pasteur 48
Merck & Co, Wyeth/Pfizer, Novartis 49
Local vaccine players 49
Fiocruz/Bio-Manguinhos 51
Instituto Butantan 56
Key future target indications 58
SWOT analysis of Brazil as a target market for vaccine producers 60
Best strategy for market penetration 62
3. Mexico 64
Key findings 64
General characteristics 65
Demographics 66
Economics 68
Healthcare expenditure and access 69
The Mexican vaccines market 71
Historic development 71
Current market situation 72
Key stakeholders in Mexico's vaccination system 75
Existing recommendations, coverage, available vaccines 76
Vaccination recommendations 76
Vaccination coverage 78
Available vaccines 79
Regulatory process for vaccines 83
Key vaccine players in Mexico 84
General overview 84
Multinational corporations 84
Sanofi Pasteur 85
Novartis 85
Merck & Co 85
GlaxoSmithKline 85
Wyeth/Pfizer 85
Local vaccine players 85
Birmex 86
Key future target indications 87
SWOT analysis of Mexico as a target market for vaccine producers 88
Best strategy for market penetration 89
4. Argentina 91
Key findings 91
General characteristics 92
Demographics 93
Economics 95
Healthcare expenditure and access 96
The Argentinean vaccines market 98
Historic development 98
Current market situation 99
Key stakeholders in Argentina's vaccination system 100
Existing recommendations, coverage, available vaccines 100
Vaccination recommendations 100
Vaccination coverage 103
Available vaccines 104
Regulatory process for vaccines 107
Key vaccine players in Argentina 107
General overview 107
Multinational corporations 108
Sanofi Pasteur 108
GlaxoSmithKline 108
Novartis 109
Merck & Co 109
Wyeth/Pfizer 109
Local vaccine players 109
Key future target indications 111
SWOT analysis of Argentina as a target market for vaccine producers 112
Best strategy for market penetration 113
Bibliography 114
Journals 114
Websites 114
Appendix 121
Contributing experts 121
Conferences attended 121
Report methodology 121
About Datamonitor 122
About Datamonitor Healthcare 122
About the Infectious Diseases analysis team 123
Key therapy team members 124
Hedwig Kresse, Lead Analyst, Infectious Diseases 124
Disclaimer 126
List of Tables
Table 1: Overview: vaccines recommended as part of the national immunization schedules in Brazil, Mexico and Argentina, 2009 12
Table 2: Pan American Health Organization (PAHO) revolving fund vaccine prices, 2009 17
Table 3: Brazil: key economic indicators, 2007-09 25
Table 4: Brazil: healthcare expenditure indicators, 2006 26
Table 5: Brazil: key health system indicators, 2006 27
Table 6: Brazil: top 10 causes of mortality, 2004 27
Table 7: Brazil: vaccination recommendations, 2009 38
Table 8: Brazil: administered vaccine doses by indication, 2005-09 42
Table 9: Brazil: position of the five key Western vaccine players, 2010 47
Table 10: Brazil: overview of key local vaccine players, 2010 50
Table 11: Fiocruz/Bio-Manguinhos: human vaccine portfolio overview, 2010 54
Table 12: Fiocruz/Bio-Manguinhos: key vaccine deals and alliances, 2010 55
Table 13: Instituto Butantan: human vaccine portfolio overview, 2010 57
Table 14: Instituto Butantan: key vaccine deals and alliances, 2010 57
Table 15: SWOT analysis of Brazil as vaccine market, 2010 62
Table 16: Mexico: key economic indicators, 2007-09 68
Table 17: Mexico: healthcare expenditure indicators, 2006 69
Table 18: Mexico: key health system indicators, 2004 70
Table 19: Mexico: top 10 causes of mortality, 2004 70
Table 20: Mexico: vaccination recommendations, 2009 78
Table 21: Mexico: authorized vaccines, November 2009 80
Table 22: Mexico: position of the five key Western vaccine players, 2010 84
Table 23: Birmex: human vaccine portfolio overview, 2010 86
Table 24: Birmex: key vaccine deals and alliances, 2010 87
Table 25: SWOT analysis of Mexico as vaccine market, 2010 89
Table 26: Argentina: key economic indicators, 2007-09 95
Table 27: Argentina: healthcare expenditure indicators, 2006 96
Table 28: Argentina: key health system indicators, 2004 97
Table 29: Argentina: top 10 causes of mortality, 2004 97
Table 30: Argentina: estimated number of vaccine doses distributed for key indications, 2010 99
Table 31: Argentina: vaccination recommendations, 2009 102
Table 32: Argentina: authorized vaccines, 2010 105
Table 33: Argentina: position of the five key Western vaccine players, 2010 108
Table 34: SWOT analysis of Argentina as vaccine market, 2010 113
List of Figures
Figure 1: Overview: total population size, Brazil, Mexico, Argentina, the US and the five major EU markets, 1995-2020 7
Figure 2: Overview: birth cohort size, Brazil, Mexico, Argentina, the US and the five major EU markets, 1995-2020 8
Figure 3: Overview: gross domestic product (GDP) per capita, Brazil, Mexico, Argentina, the US and the five major EU markets, 2007-09 9
Figure 4: Overview: healthcare spend per capita and private expenditure on health in Brazil, Mexico, Argentina, the US and the five major EU markets, 2006 10
Figure 5: Overview: distribution of key endemic diseases in Latin America 11
Figure 6: Overview: coverage for key vaccinations in Brazil, Mexico and Argentina, 2008 13
Figure 7: Market shares of key Western vaccine companies in Latin America, 2008 14
Figure 8: Overview: estimates of the market size for human vaccines in Brazil, Mexico and Argentina, 2008/2009 15
Figure 9: National versus external vaccine financing, Latin America, 1987-2006 16
Figure 10: Overview: key domestic vaccine players in Brazil, Mexico and Argentina, 2010 18
Figure 11: Overview: key vaccine market characteristics in Brazil, Mexico and Argentina, 2010 19
Figure 12: Brazil: overview of the vaccine landscape, 2010 21
Figure 13: Brazil: population growth, 1995-2020 22
Figure 14: Brazil: population spread by age group, 2010 versus 2020 23
Figure 15: Brazil: mortality of children <5 years of age, 1995-2020 24
Figure 16: Brazil: timeline of introduction of key vaccines into the public immunization schedule, 1973-2010 29
Figure 17: Brazil: Programa Nacional de Imunizações (PNI), vaccine purchase budget, 1995-2007 30
Figure 18: Brazil: vaccine imports by indication, 2005-09 33
Figure 19: Brazil: vaccine imports by country of origin, 2005-09 34
Figure 20: Brazil: vaccination schedule published by Ministério da Saúde , 2009 36
Figure 21: Brazil: vaccination schedule published by Associação Brasileira de Imunizações, 2009 37
Figure 22: Brazil: vaccination coverage, 2004-08 40
Figure 23: Brazil: administered vaccine doses by indication, 2005-09 41
Figure 24: Brazil: local vaccine production versus imports for public sector vaccines, 1996-2000 45
Figure 25: Brazil: contribution of multinational vaccine makers to product supply for private sector immunization, 2001 46
Figure 26: Brazil: Sanofi Pasteur net vaccine sales, 2005-09 48
Figure 27: Share of Fiocruz/Bio-Manguinhos among Brazilian vaccine suppliers for the National Immunization Program; 2001-07 51
Figure 28: Fiocruz/Bio-Manguinhos: vaccine sales 2001-07 52
Figure 29: Fiocruz/Bio-Manguinhos: exported doses of yellow fever vaccine, 2001-07 53
Figure 30: Brazil: key future target vaccine indications, 2010 59
Figure 31: Mexico: overview of the vaccine landscape, 2010 65
Figure 32: Mexico: population growth, 1995-2020 66
Figure 33: Mexico: population spread by age group, 2010 versus 2020 67
Figure 34: Mexico: mortality of children <5 years of age, 1995-2020 68
Figure 35: Mexico: timeline of introduction of key vaccines into the public immunization schedule, 1951-2008 72
Figure 36: Mexico: applied vaccine doses by indication, 2007 74
Figure 37: Mexico: applied vaccine doses by indication and month, 2007 75
Figure 38: Mexico: applied vaccine doses by place of administration, 2007 76
Figure 39: Mexico: vaccination schedule, 2009 77
Figure 40: Mexico: vaccination coverage, 2004-08 79
Figure 41: Mexico: key future target vaccine indications, 2010 88
Figure 42: Argentina: overview of the vaccine landscape, 2010 92
Figure 43: Argentina: population growth, 1995-2020 93
Figure 44: Argentina: population spread by age group, 2010 versus 2020 94
Figure 45: Argentina: mortality of children <5 years of age, 1995-2020 95
Figure 46: Argentina: timeline of introduction of key vaccines into the public immunization schedule 98
Figure 47: Argentina: vaccination schedule, 2009 101
Figure 48: Argentina: vaccination coverage, 2004-08 103
Figure 49: Argentina: vaccination coverage by region, 2007 104
Figure 50: Argentina: key future target vaccine indications, 2010 112

[Inhaltsverzeichnis ausblenden]